We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
News

Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate

Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
News

Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rosetta Genomics has announced that it has signed a non-exclusive licensing agreement with Rockefeller University for research application of proprietary microRNA genes. The agreement encompasses viral and human microRNAs that will be added to Rosetta Genomics' existing intellectual property (IP) estate, which includes two issued patents, two allowed patent applications, and 60 pending patent applications.

"As leaders in the microRNA field, we view our strong intellectual property position as a key component of our business strategy, allowing us the freedom to advance the company and its pipeline." said Amir Avniel, President and CEO of Rosetta. "Our strategy continues to focus on supplementing our in-house IP portfolio with licensing agreements with key academic centers such as Rockefeller University."

Rosetta Genomics has previously licensed Rockefeller University's proprietary microRNAs for therapeutic and diagnostic uses, and this recent agreement allows the company access to a full range of potential microRNA applications based on these microRNAs.

In addition to its non-exclusive license of Rockefeller University's microRNAs, Rosetta Genomics estimates it has exclusive access to the majority of known microRNA genes through proprietary microRNAs discovered at Rosetta Genomics and microRNAs co-discovered by The Johns Hopkins University School of Medicine and exclusively licensed to the Company.

In addition, the Company has non-exclusively licensed for research and diagnostic applications microRNAs discovered by the Max Planck Society. From this strong IP position, Rosetta Genomics is developing a wide range of microRNA-based diagnostic tests for cancer and other indications.

Advertisement